In addition to developing dual inhibitors that simultaneously block the activity of both AURKA and its cancer-driving substrates, another approach could involve designing molecules that specifically disrupt the interaction between AURKA and its substrates, thereby inhibiting their oncogenic functions. Here, AURKA is linked to cancer.